Journal
CYTOTHERAPY
Volume 23, Issue 5, Pages 390-398Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.jcyt.2020.07.006
Keywords
Cell and gene therapy; rapid microbial testing methods; standards; sterility
Ask authors/readers for more resources
The SCB supports the development and commercialization of regenerative medicine products by addressing industry-wide challenges through standards, with a focus on rapid microbial testing methods. Efforts are being made to develop documentary standards for risk-based approach in selecting fit-for-purpose assays and sampling methods for microbial testing in tissue-engineered medical products. The SCB is also facilitating the process of developing publicly available microbial materials for inter-laboratory testing to validate novel rapid methods.
The Standards Coordinating Body for Gene, Cell, and Regenerative Medicines and Cell-Based Drug Discovery (SCB) supports the development and commercialization of regenerative medicine products by identifying and addressing industry-wide challenges through standards. Through extensive stakeholder engagement, the implementation of rapid microbial testing methods (RMTMs) was identified as a high-priority need that must be addressed to facilitate more timely release of products. Since 2017, SCB has coordinated efforts to develop standards for this area through surveys, weekly meetings, workshops, leadership in working groups and participation in standards development organizations. This article describes the results of these efforts and discusses the current landscape of RMTMs for regenerative medicine products. Based on discussions with stakeholders across the field, an overview of traditional culture-based methods and limitations, alternative microbial testing technologies and current challenges, fit-for-purpose rapid microbial testing and case studies, risk-based strategies for selection of novel rapid microbial test methods and ongoing standards efforts for rapid microbial testing are captured here. To this end, SCB is facilitating several initiatives to address challenges associated with rapid microbial testing for regenerative medicine products. Two documentary standards are under development: an International Organization for Standardization standard to provide the framework for a risk-based approach to selecting fit-for-purpose assays primarily intended for cell and gene therapy products and an ASTM standard guide focused on sampling methods for microbial testing methods in tissue-engineered medical products. Working with the National Institute of Standards and Technology, SCB expects to facilitate the process of developing publicly available microbial materials for inter-laboratory testing. These studies will help collect the data necessary to facilitate validation of novel rapid methods. Finally, SCB has been working to increase awareness of, dialog about and participation in efforts to develop standards in the regenerative medicine field. (c) 2021 Published by Elsevier Inc. on behalf of International Society for Cell & Gene Therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available